Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TARBP2 | Q15633 | 3/20 | 0.41 |
| ▸ | TDP2 | O95551 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12416429 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S | |
| SCHEMBL22609347 | 0.81 | NPSR1 (0.45) | ALDH1A1 | |
| SCHEMBL29044483 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S | |
| SCHEMBL23596005 | 0.79 | TDP1 (0.47) | ALDH1A1HTTKDM4E | |
| SCHEMBL12416482 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S | |
| SCHEMBL841887 | 0.78 | HTR2C (0.38) | ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S | |
| SCHEMBL353667 | 0.77 | ALDH1A1 (0.57) | ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S | |
| SCHEMBL2733993 | 0.77 | ALDH1A1 (0.57) | ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S | |
| SCHEMBL1806542 | 0.77 | MAPT (0.37) | ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S | |
| SCHEMBL12926059 | 0.76 | ALDH1A1 (0.46) | ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021009068-A1 | N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME | SCENIC IMMUNOLOGY B.V. (NL) | 2021-01-21 | — | — | WO | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | ALDH1A1 2410/4885MLYCD 2358/4885CACNA1F 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.